Prediction: The Next Eli Lilly Might Already Be Trading Under $50

Prediction: The Next Eli Lilly Might Already Be Trading Under $50

Key PointsViking Therapeutics is developing a weight loss medicine in the same general class as Eli Lilly's tirzepatide.The mid-cap biotech is exploring options for a potential quadruple agonist therapy.Though Viking looks promising, there are also significant risks involved. 10 stocks we like better than Viking Therapeutics › Eli Lilly (NYSE: LLY) produced exceptional returns over the long run and is now the largest pharmaceutical company in th…